The Importance Of Polymorph Screenings

By Giovanna Brancatelli, Ph.D., Scientific Director, Solid State Research

Polymorphism can profoundly influence the stability, solubility, bioavailability, and manufacturability of small‑molecule drug substances. Different crystalline forms of the same compound may emerge during synthesis, processing, or storage, sometimes with serious consequences for product quality and clinical performance. Understanding and controlling this behavior early is essential to avoid costly delays, reformulation, or market withdrawal. A structured polymorph screening strategy identifies thermodynamically stable and metastable forms, hydrates, and solvates, while clarifying how processing conditions such as solvent choice, temperature, pressure, and mechanical stress affect solid‑state outcomes. Beyond risk mitigation, polymorph knowledge supports robust manufacturing processes and strengthens intellectual property by enabling the protection of distinct solid forms.

A phase‑appropriate approach balances scientific depth with material availability, timing, and cost—starting with focused early screens and expanding as development progresses. Together, these practices provide the foundation for consistent drug performance, regulatory confidence, and long‑term product reliability from early development through commercialization.